An update on pharmacologic management of chronic obstructive pulmonary disease

Hetal J. Patel

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations


Purpose of review Chronic obstructive pulmonary disease (COPD) is a widespread disease process with important clinical and economic implications. This review will summarize new pharmacotherapy for the treatment of COPD. Recent findings Several recent clinical trials have led to the approval of new inhaler therapies for COPD. Many of these are specifically targeting combination long-acting β-agonists and long-acting muscarinic antagonists for late stage COPD. Summary Several new bronchodilators are available on the market, especially in combination form. The new drug combinations have positive data though clinical relevance, and comparisons to available and well established therapies are still needed. Specifically, translating improved forced expiratory volume into meaningful clinical outcomes remains challenging.

Original languageEnglish (US)
Pages (from-to)119-124
Number of pages6
JournalCurrent Opinion in Pulmonary Medicine
Issue number2
StatePublished - Mar 1 2016


  • chronic obstructive pulmonary disease
  • long-acting muscarinic antagonists
  • long-acting β-agonists

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine


Dive into the research topics of 'An update on pharmacologic management of chronic obstructive pulmonary disease'. Together they form a unique fingerprint.

Cite this